|Report ID : RNR-78228||Category : Biotechnology||Published Date : May 2017|
|Publisher : 9Dimen||Pages : 156||Format : PDF|
The global NGS-based RNA-seq market is projected to reach USD 2.65 billion by 2022 from USD 1.05 billion in 2017, at a CAGR of 20.2%. Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the NGS-based RNA-seq market. On the other hand, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market. Market Segments In 2016, the sequencing platforms and consumables segment is expected to account for the largest share of the market. The data analysis, storage, and management is expected to register the highest growth rate owing to its development of more efficient data analysis solutions and growing computational capabilities of data analytics providers. Research centers and academic & government institutes segment accounted for the largest share of the global market in 2016 due to the increasing focus of market players on providing efficient RNA-seq products & services for research applications and the growing number of government funding programs. However, the hospitals and clinics segment is expected to register the highest growth due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-seq market owing to the technological advantages of expression profiling applications. Largest and Fastest Geographical Market Geographically, the NGS-based RNA-seq market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe and Asia-Pasific. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, owing to focus on R&D activities and the low cost of NGS products & services in this region. Breakdown of supply-side primary interviews: by company type, designation, and region: • By Company Type - Tier 1 – 33%, Tier 2 – 50% and Tier 3 – 17% • By Designation – C level – 35%, Director level – 25%, Others – 40% • By Region – North America - 24%, Europe – 19%, APAC – 33%, RoW – 24% Growth Strategies The global NGS-based RNA-seq market is highly competitive, with a large number of global and local players. In 2016, the market was dominated by Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Pacific Biosciences of California, Inc. (U.S.). Product launches, agreements, and partnerships were the major strategies adopted by market players to achieve growth in the market. Research Coverage This report studies the NGS-based RNA-seq market based on product & service, application, technology, and end user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions. Reasons to Buy the Report: From an insights perspective, this research report has focused on various levels of analysis—industry trends, market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the NGS-based RNA-seq market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies for strengthening their market shares. The report provides insights on the following pointers: • Market Penetration: Comprehensive information on product portfolios and services offered by the major players in the NGS-based RNA-seq market. The report analyzes the NGS-based RNA-seq market based on product & service, application, technology, end user, and region • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the NGS-based RNA-seq market • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various NGS-based RNA-seq products and services across geographies • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-seq market • Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the NGS-based RNA-seq market
1 Introduction 1.1 Objectives Of The Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Markets Covered 1.3.2 Geographic Scope 1.3.3 Years Considered For The Study 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2 Research Methodology 2.1 Research Methodology Steps 2.2 Research Design 2.3 Secondary And Primary Research Methodology 2.3.1 Secondary Research 184.108.40.206 Key Data From Secondary Sources 2.3.2 Primary Data 220.127.116.11 Key Data From Primary Sources 18.104.22.168 Key Industry Insights 2.4 Market Size Estimation 22.214.171.124 Bottom-up Approach 126.96.36.199 Top-down Approach 2.5 Market Breakdown And Data Triangulation 2.6 Assumptions For The Study 3 Executive Summary 3.1 Introduction 4 Premium Insights 4.1 Ngs-based Rna-seq Market Overview 4.2 Ngs-based Rna-seq Market Growth Rate, By Technology, 2017 Vs. 2022 (Usd Million) 4.3 Ngs-based Rna-seq Market, By Application And Region, 2017 (Usd Million) 4.4 Ngs-based Rna-seq Market, By End User, 2017 Vs. 2022 4.5 Geographical Snapshot Of The Ngs-based Rna-seq Market ? 5 Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 188.8.131.52 Advantages Of Rna-seq Over Microarray Technology 184.108.40.206 Technological Advancements In Rna-seq Products 220.127.116.11 Increasing Number Of Rna-seq Grants 18.104.22.168 Increasing Number Of Research Activities Involving Rna-seq 22.214.171.124 Rapid Growth In Precision Medicine 5.2.2 Restraints 126.96.36.199 Lack Of Skilled Professionals 188.8.131.52 Standardization Concerns Of Rna-seq In Diagnostic Testing 5.2.3 Opportunities 184.108.40.206 Increasing Applications Of Rna-seq In Research 220.127.116.11.1 Cancer Research 18.104.22.168.2 Agricultural Research 5.2.4 Challenges 22.214.171.124 Storage & Interpretation Of Sequencing Data 126.96.36.199 Analysis Of Rna-seq Data For Detection Of Novel Transcripts 5.3 Industry Trends 5.3.1 Growing Number Of Strategic Partnerships And Collaborations 5.3.2 Increasing Number Of Conferences And Workshops Related To Rna-seq 6 Global Ngs-based Rna Sequencing Market, By Product & Service 6.1 Introduction 6.1.1 Sample Preparation 188.8.131.52 Sample Preparation, By Workflow Step 184.108.40.206.1 Fragmentation, End Repair, And Size Selection 220.127.116.11.2 Library Preparation And Target Enrichment 18.104.22.168.3 Quality Control 22.214.171.124 Sample Preparation, By Method 126.96.36.199.1 Manual Sample Preparation 188.8.131.52.2 Microfluidic Sample Preparation 184.108.40.206.3 Robotic Liquid Handling Sample Preparation 6.1.2 Sequencing Platforms And Consumables 6.1.3 Sequencing Services 6.1.4 Data Analysis, Storage, And Management ? 7 Global Ngs-based Rna Sequencing Market, By Technology 7.1 Introduction 7.2 Sequencing By Synthesis 7.3 Ion Semiconductor Sequencing 7.4 Single-molecule Real-time Sequencing 7.5 Nanopore Sequencing 8 Global Ngs-based Rna Sequencing Market, By Application 8.1 Introduction 8.2 Expression Profiling Analysis 8.3 Small Rna Sequencing 8.4 De Novo Transcriptome Assembly 8.5 Variant Calling And Transcriptome Epigenetics 9 Global Ngs-based Rna Sequencing Market, By End User 9.1 Introduction 9.2 Research Centers And Academic & Government Institutes 9.3 Hospitals & Clinics 9.4 Pharmaceutical & Biotechnology Companies 9.5 Other End Users 10 Global Ngs-based Rna Sequencing Market, By Region 10.1 Introduction 10.2 North America 10.2.1 U.S. 10.2.2 Canada 10.3 Europe 10.4 Asia-pacific 10.5 Rest Of The World 11 Competitive Landscape 11.1 Business Overview 11.2 Vendor Inclusion Criteria 11.3 Vendor Dive 11.3.1 Vanguards 11.3.2 Innovators 11.3.3 Dynamic Players 11.3.4 Emerging Players ? 11.4 Competitive Benchmarking 11.4.1 Product Offering (For All 25 Companies) 11.4.2 Business Strategy (For All 25 Companies) *Top 25 Companies Analyzed For This Study Are - Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Pacific Biosciences Of California, Inc. (U.S.), Oxford Nanopore Technologies (U.K.), Perkinelmer, Inc. , (U.S.), Qaigen N.V. (Germany), F. Hoffmann-la Roche Ag (Switzerland), Agilent Technologies (U.S.), Bio-rad Laboratories, Inc. (U.S.), Gatc Biotech Ag (Germany), Macrogen, Inc. (South Korea), Eurofins Scientific (Luxembourg), Bgi (China), Takara Holdings Inc. (Japan), Cofactor Genomics, Inc. (U.S.), Otogenetics Corporation (U.S.), Nugen Technologies Inc. (U.S.), Hamilton Company (U.S.), Intrexon Corp. (U.S.), 10x Genomics, Inc. (U.S.), Personalis Inc. (U.S.), Genewiz, Inc. (U.S.), Medgenome Inc. (U.S.), Novogene Corporation (China), And Biomatters Ltd. (New Zealand) 12 Company Profiles (Overview, Products And Services, Financials, Strategy & Development)* 12.1 Illumina, Inc. 12.2 Thermo Fisher Scientific Inc. 12.3 Pacific Biosciences Of California, Inc. 12.4 Qaigen N.V. 12.5 F. Hoffmann-la Roche Ag 12.6 Agilent Technologies, Inc. 12.7 Bgi (Beijing Genomics Institute) 12.8 Oxford Nanopore Technologies, Ltd 12.9 Perkinelmer, Inc. 12.10 Eurofins Scientific 12.11 Gatc Biotech Ag 12.12 Macrogen, Inc. *Details On Overview, Products And Services, Financials, Strategy & Development Might Not Be Captured In Case Of Unlisted Companies.